PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 206 filers reported holding PDL BIOPHARMA INC in Q4 2015. The put-call ratio across all filers is 0.15 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $63,000 | -98.5% | 29,531 | -97.7% | 0.00% | -98.2% |
Q3 2016 | $4,242,000 | -41.1% | 1,266,121 | -44.8% | 0.06% | -36.0% |
Q2 2016 | $7,202,000 | -42.1% | 2,293,523 | -38.6% | 0.09% | -38.1% |
Q1 2016 | $12,430,000 | -26.1% | 3,732,679 | -21.4% | 0.14% | -24.0% |
Q4 2015 | $16,810,000 | -33.8% | 4,748,690 | -5.9% | 0.18% | -26.2% |
Q3 2015 | $25,383,000 | -45.4% | 5,046,353 | -30.2% | 0.25% | -36.2% |
Q2 2015 | $46,514,000 | +96.5% | 7,233,838 | +114.9% | 0.39% | +114.9% |
Q1 2015 | $23,676,000 | +1578.0% | 3,365,474 | +1739.0% | 0.18% | +1545.5% |
Q4 2014 | $1,411,000 | +627.3% | 183,003 | +603.9% | 0.01% | +450.0% |
Q3 2014 | $194,000 | -97.5% | 25,997 | -96.7% | 0.00% | -97.9% |
Q2 2014 | $7,645,000 | -44.8% | 789,804 | -52.6% | 0.10% | -53.8% |
Q1 2014 | $13,841,000 | -51.0% | 1,665,543 | -50.2% | 0.21% | -69.0% |
Q4 2013 | $28,223,000 | +22.5% | 3,343,973 | +15.7% | 0.67% | -10.2% |
Q3 2013 | $23,038,000 | +28.9% | 2,890,564 | +24.8% | 0.75% | -2.3% |
Q2 2013 | $17,875,000 | – | 2,315,381 | – | 0.77% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |